ERIKA KELSO: Open Payments
NPI 1396289930 · SCHERTZ, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,068 in 50 payments from 13 companies in 2025. Trend: 2023 $1,825 · 2024 $1,182 · 2025 $1,068
Food & beverage: $978Education: $90
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 8 | $188 |
| Galderma Laboratories, L.P. | 10 | $164 |
| Janssen Biotech, Inc. | 3 | $137 |
| UCB, Inc. | 4 | $107 |
| Novartis Pharmaceuticals Corporation | 5 | $105 |
| Incyte Corporation | 4 | $88 |
| ABBVIE INC. | 3 | $65 |
| Organon LLC | 6 | $60 |
| E.R. Squibb & Sons, L.L.C. | 2 | $51 |
| Lilly USA, LLC | 2 | $39 |
Products named: DUPIXENT, NEMLUVIO, TREMFYA, Bimzelx, OPZELURA, COSENTYX, Sotyktu, SKYRIZI.
Industry payments across TX — which companies pay providers there.
